-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tadekinig Alfa in Hemophagocytic Lymphohistiocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tadekinig Alfa in Hemophagocytic Lymphohistiocytosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tadekinig Alfa in Hemophagocytic Lymphohistiocytosis Drug Details: Tadekinig alfa is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tadekinig Alfa in Lymphoproliferative Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tadekinig Alfa in Lymphoproliferative Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tadekinig Alfa in Lymphoproliferative Disorders Drug Details: Tadekinig alfa is...
-
Product Insights
NewHemophagocytic Lymphohistiocytosis – Drugs In Development, 2024
Empower your strategies with our Hemophagocytic Lymphohistiocytosis – Drugs In Development, 2024 report and make more profitable business decisions. Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic or haemophagocytic syndrome is an uncommon hematologic disorder and is a life-threatening disease of severe hyperinflammation caused by uncontrolled proliferation of benign lymphocytes and macrophages that secrete high amounts of inflammatory cytokines. It is seen more often in children than in adults. HLH results from immune over-activation owing to some combination of inappropriate immunologic (CD8+...
-
Product Insights
NewLymphoproliferative Disorders – Drugs In Development, 2024
Empower your strategies with our Lymphoproliferative Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Lymphoproliferative disorders (LPD) constitute a diverse group of diseases marked by uncontrolled lymphocyte production, resulting in monoclonal lymphocytosis, lymphadenopathy, and bone marrow infiltration. Predominantly affecting immunocompromised individuals, these disorders involve two subsets of lymphocytes, T and B cells, leading to immunoproliferative disorders with inherent risks of immunodeficiency and lymphocyte dysregulation. Causative gene mutations, whether iatrogenic or acquired, are identified through somatic or...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tadekinig alfa
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tadekinig alfa Drug Details Tadekinig alfa is under development for the treatment of adult-onset...
-
Product Insights
Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Obstructive Pulmonary Disease (COPD) symptoms include inability to completely breathe out air from the lungs leading to shortness of breath. Other symptoms include cough, fatigue, and chest pain. The COPD pipeline drugs market research report provides an analysis of the COPD drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest...
-
Product Insights
Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants. The KCS pipeline drugs market research report provides an analysis of the KCS drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...